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A clinical pathway was created to feed information into a clinical audit checklist, and was adopted as 
the patient-management model for biological therapies. From this, the data was reviewed concerning 
41 patients who were receiving SEC between January 2014 and December 2018. The results for the 
Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) score which are 
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Abrouk et al., (2017) acknowledged that, regardless of the 
wide range of currently available treatments for psoriasis, 
refractory disease remains a problem.1 Whilst the safety of 
Secukinumab (SEC) is well established, there are insufficient 
head-to-head studies currently available to compare SEC 
efficacy to other biologicals whose use is currently 
established.2  
 
The ‘biologicals’ represent a powerful class of agents with 
very specific actions. They are expensive therapies placing a 
duty on healthcare providers to ensure they are used for the 
most appropriate patients. New products with novel modes of 
action are emerging regularly.  Also as patent protection 
expires, owing to the complexity of manufacture and the 
difficulties in ensuring products from ‘generic’ manufacturers 
are identical, the concept of ‘biosimilars’ has emerged. To 
achieve the best outcomes for our patients whilst ensuring the 
best possible use of available resources requires novel 
approaches to day to day management.3 
 
SEC is a fully human monoclonal antibody that selectively 
neutralizes interleukin IL-17A, a key cytokine involved in the 
development of psoriasis (PsO).4Superior efficacy5and 
sustainable response for up to 5 years had been reported in 
clinical trials.6In placebo-controlled trials SEC significantly 
improved clinical symptoms and inhibited structural 
progression at week 24 in patients with Psoriatic Arthritis 
(PsA), with and without the use of a loading dose.7Reporting 
further for the FUTURE trial group, Mease et al., (2018) 
indicated that SEC was well tolerated noting no new safety 
signals.8Consequently, it was considered to offer an effective 
new addition to the current therapeutic options in PsA.9 
 
In the FUTURE studies, 476 patients receiving SEC achieved 
sustained improvement in their PsA and tolerated the treatment 
for 2 years.2Langley et al., (2014) concluded that, based on the 
findings from the ERASURE and FIXTURE randomised 
studies, that SEC is effective for PsO management at 12 week 
patient reviews, however the response varied by dose, “In the 
ERASURE study, the rates were 65.3% with 300 mg of SEC, 
51.2% with 150 mg of SEC, and 2.4% with placebo; in the 
FIXTURE study, the rates were 62.5% with 300 mg of SEC, 
51.1% with 150 mg of SEC, 27.2% with etanercept, and 2.8% 
with placebo (P<0.001 for each SEC dose vs. comparators)”, 
where infection rate for SEC was higher than with placebo but 
similar to etanercept.10This conclusion confirms the finding by 
Bissonnette et al., (2018) who stated that SEC higher dose 
(300 mg) produced “high and sustained levels of skin 
clearance” improving the participants quality of life 
throughout and up to the 5 years follow up in patients with 
moderate-to-severe psoriasis.11This also agrees with Yang et 
al., (2018) who stated that selection of patients classified as 
“moderate-to-severe psoriasis” is a key consideration for the 
use of SEC.12Malakouti et al., (2015) also concluded that 
patients treated with SEC achieved “high clearance rates up to 
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PASI 90 and 100 as monotherapy in cases of moderate-to-
severe psoriasis”, and that it is a favourable treatment option 
for those with have antidrug antibodies, have failed other 
biologic agents and those diagnosed with psoriatic arthritis or 
ankylosing spondylitis.13 
 
However, trials are conducted under carefully controlled 
conditions, and for all new treatments there is a need for ‘real 
world data’in patients with multiple pathologies, multiple other 
medications and those whose adherence to therapy may not be 
closely monitored. Further, increasing availability of 
‘biosimilars’ in the marketplace is creating drivers to reduce 
costs, but in the interests of patient safety and quality of life, it 
is important for centres like this one, to be in a position to 
make realistic comparisons.3 
 
METHOD AND DESIGN 
 
The aim of this audit was to test our model for monitoring our 
patients to identify whether when SEC was prescribed for a 
patient of this department, the baseline characteristics of their 
condition and demographics and their clinical experience of 
the medication had been recorded in such a way that the 
department is in a position to retrospectively review their 
progress and any issues experienced with this medication. 
 
This aims to provide 
 
1. Data to audit our clinical experience with SEC in our 
patient population with our normal follow-up. 
2. To provide baseline comparison data against which 
future competitor agents or ‘biosimilars’ could be 
assessed. 
3. To review our ongoing audit model for future use with 
all biological agents in our referral service. 
 
Patients prescribed SEC were identified from our pharmacy 
database and data were collected from electronic patient 




According to NICE guidelines (NICE TA350):14,15 
 
1. Initiation of therapy should be as 150 mg every week  
2. After 150 mg every week for 5 doses, the maintenance 
150 mg every month, dose may be increased to 300 mg 
according to clinical response 
3. SEC should be withdrawn in patients whose psoriasis 
has not responded adequately within 12 weeks of initial 
dose; further treatment cycles are not recommended. 
 
Our normal care protocol is for the PASI and DLQI to be 
conducted to confirm patient eligibility for the initiation of 
SEC. These are repeated at 11-12 weeks to establish the 
patient’s response before continuation of therapy beyond the 
12 weeks. In this audit we compared the baseline and at 16 
weeks PASI and DLQI scores to assess the response seen in 




Forty-one patients who had been deemed appropriate for SEC 
treatment were identified of whom thirty-seven were males 
(90.24%).The mean age was 47.85 ± 11.81 (n=41). The mean 
baseline PASI score was 16.43 ± 5.68 (n=39) and the mean 
baseline DLQI was 20.26 ± 6.16. The proportion of patients 
that were bio-naive was 36.58% (15/41). It is not currently our 
routine practice to monitor adherence. Patients trained on self-
injection at home. 
The response to the treatment was assessed at 16 weeks.  There 
was an 83.26% reduction of mean PASI score at 2.75 ± 3.21 
(n=26) and the mean DLQI score was 3.61 ± 4.53 (82.18% 
reduction from baseline). About 92%(24/26) of the total 
population met the NICE criteria for remaining on treatment; 
attaining at least a PASI 75 or a PASI 50 plusa 5 points 
reduction in DLQI. PASI 75 was achieved by 84.62% (22/26), 
whereas 53.85% (14/26) of the population achieved a PASI 90 
and 26.92% (7/26) achieved PASI 100. No unusual adverse 
events were observed. 
 
No patients volunteered information on adverse effects, on 
questioning 1/41 reported some rhinorrhoea.  No reports of 




Our early findings are reported, and appear broadly in line 
with the types of response seen in formal trials. It is 
encouraging that the patients have met and exceeded the NICE 
criteria to be able to continue with therapy that is proving 
highly effective and that the side effect profile appears to 
continue to be favourable.  
 
Our routine practice does not currently include any assessment 
or monitoring of adherence. The clinical responses measured 
suggest it is reasonable, although previous studies have 
demonstrated resistance to self-administered injections.16-
17Possible ways of including adherence 





Our data demonstrates real life clinical outcomes of SEC in a 
cohort of PsO patients in the real world, with more than 90% 
patients meeting NICE criteria to treatment continuation at 16 
weeks. More research is required to assess the sustainability of 
efficacy in these patients beyond 16 weeks, in real time and in 
community living, of treatment outside of clinical controlled 
trials. 
 
In the context of expensive therapies that must be justified by 
clinical effectiveness, and the substitution of biosimilars, an 
approach that allows regular audit of clinical outcomes and 
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